

**TERMINAL DISCLAIMER ACCOMPANYING A RENEWED PETITION
UNDER 37 CFR 1.182**

Docket Number (Optional)

051058-034000

In re Application of: Pachuk et al.

Application No.: New Continuation-in-Part of Application Serial No. 10/560,377, generated upon grant of the renewed petition under 37 CFR 1.182 filed herewith.

Filed: 8/17/2010

For: CONSERVED HBV AND HCV SEQUENCES USEFUL FOR GENE SILENCING

The owners*, ALNYLAM PHARMACEUTICALS, INC., of 100 percent interest in the above-noted Continuation-in-Part application and its parent application, hereby disclaim the terminal part of the statutory term of any patent granted on the instant application, between the filing date of a grantable petition under 37 C.F.R. 1.182 to create the Continuation-in-Part, filed herewith, and the filing date under 35 U.S.C. 111(a) of such application. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

Check either box 1 or 2, if appropriate.

1. ☐ For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2. ☒ The undersigned is an attorney or agent of record.

Signature

August 24, 2010
Date

Mark J. FitzGerald (Reg. No. 45,928)
Typed or printed name

- ☒ Terminal disclaimer fee under 37 CFR 1.20(d) is included.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

*Statement under 37 CF 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this statement. See MPEP § 324.